APA
Arnedo-Valero M., Garcia F., Gil C., Guila T., Fumero E., Castro P., Blanco J. L., Miró J. M., Pumarola T. & Gatell J. M. (20060925). Risk of selecting de novo drug-resistance mutations during structured treatment interruptions in patients with chronic HIV infection. : Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
Chicago
Arnedo-Valero M, Garcia F, Gil C, Guila T, Fumero E, Castro P, Blanco J L, Miró J M, Pumarola T and Gatell J M. 20060925. Risk of selecting de novo drug-resistance mutations during structured treatment interruptions in patients with chronic HIV infection. : Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
Harvard
Arnedo-Valero M., Garcia F., Gil C., Guila T., Fumero E., Castro P., Blanco J. L., Miró J. M., Pumarola T. and Gatell J. M. (20060925). Risk of selecting de novo drug-resistance mutations during structured treatment interruptions in patients with chronic HIV infection. : Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
MLA
Arnedo-Valero M, Garcia F, Gil C, Guila T, Fumero E, Castro P, Blanco J L, Miró J M, Pumarola T and Gatell J M. Risk of selecting de novo drug-resistance mutations during structured treatment interruptions in patients with chronic HIV infection. : Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 20060925.